In Vitro Assay for Drug-induced Hepatosteatosis Using Rat Primary Hepatocytes, a Fluorescent Lipid Analog and Gene Expression Analysis
Overview
Affiliations
To evaluate new drugs' potential for hepatosteatosis, we developed a cell-based assay using a fluorescent fatty acid analog: BODIPY558/568 C12. Rat primary hepatocytes were exposed to positive reference compounds [cyclosporine A (CsA), clofibrate (CFR), tetracycline (TC), valproic acid (VPA), carbon tetrachloride (CCl4), tamoxifen (TMX)] in the presence of BODIPY558/568 C12. The formation of fluorscecent particles or lipid droplets in the cytoplasm was confirmed by confocal laser scanning microscopy and electron microscopy respectively. The accumulation of BODIPY558/568 C12 was measured by fluorometry and high content imaging method. All positive reference compounds increased fluorescent particles in number and fluorescence intensity. High content imaging was more sensitive and selective method than fluorometry to detect fluorescent particles. Gene expression analysis of the hepatocytes showed two patterns: genes related to lipid metabolism/synthesis were down-regulated by oxidative stress inducing compounds: CsA, TC and TMX, and up-regulated by peroxisome proliferator-activated receptor-alpha agonists: CFR and VPA. From these findings, we concluded that the cell-based assay developed in this study is an appropriate method to predict drugs' potential for hepatosteatosis, and gene expression analysis is useful to profile the mechanism of the hepatosteatosis.
Yang W, Pan Q, Li Q, Zhou S, Cao X Curr Res Toxicol. 2025; 8():100213.
PMID: 39834517 PMC: 11743863. DOI: 10.1016/j.crtox.2024.100213.
Alicea G, Rebecca V, Goldman A, Fane M, Douglass S, Behera R Cancer Discov. 2020; 10(9):1282-1295.
PMID: 32499221 PMC: 7483379. DOI: 10.1158/2159-8290.CD-20-0329.
Gilglioni E, Chang J, Duijst S, Go S, Adam A, Hoekstra R Hepatol Commun. 2018; 2(3):299-312.
PMID: 29507904 PMC: 5831026. DOI: 10.1002/hep4.1140.
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.
Willebrords J, Pereira I, Maes M, Crespo Yanguas S, Colle I, Van den Bossche B Prog Lipid Res. 2015; 59:106-25.
PMID: 26073454 PMC: 4596006. DOI: 10.1016/j.plipres.2015.05.002.
Szalowska E, van der Burg B, Man H, Hendriksen P, Peijnenburg A PLoS One. 2014; 9(1):e86795.
PMID: 24489787 PMC: 3906077. DOI: 10.1371/journal.pone.0086795.